1 Sodium Intake during Pregnancy, but Not Other Diet Recommendations Aimed at Preventing Cardiovascular Disease, Is Positively Related to Risk of Hypertensive Disorders of Pregnancy.

2 The effects of Engelhardtia chrysolepis Hance on long-term memory and potential dopamine involvement in mice.

3 An increasing trend of neonatal invasive multidrug-resistant group B streptococcus infections in southern China, 2011–2017 [Corrigendum]

4 Association between vitamin D and latent tuberculosis infection in the United States: NHANES, 2011–2012

5 Evaluating the antimicrobial resistance patterns among major bacterial pathogens isolated from clinical specimens taken from patients in Mofid Children’s Hospital, Tehran, Iran: 2013–2018

6 A high prevalence of human T-lymphotropic virus (HTLV 1/2) infection among Afro-descendants, Esmeraldas province, Ecuador – need for the implementation of surveys and control programs

7 Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with Escherichia coli, ESBL-producing or not – a retrospective cohort study

8 Spinal brucellosis in Hulunbuir, China, 2011–2016

9 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

10 Low prevalence of resistance genes in sheltered homeless population in Marseille, France, 2014–2018

11 Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo

12 Susceptibilities of Gram-negative bacilli from hospital- and community-acquired intra-abdominal and urinary tract infections: a 2016–2017 update of the Chinese SMART study

13 Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016

14 Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate–severe Gram-positive infections [Corrigendum]

15 Silencing of OCH1 unveils the role of Sporothrix schenckii N-linked glycans during the host–fungus interaction

16 An increasing trend of neonatal invasive multidrug-resistant group B streptococcus infections in southern China, 2011–2017

17 Epidemiological and molecular analysis of avian influenza A(H7N9) virus in Shanghai, China, 2013–2017

18 Health care-associated infections – an overview

19 A multicenter epidemiology study on the risk factors and clinical outcomes of nosocomial intra-abdominal infections in China: results from the Chinese antimicrobial resistance surveillance of nosocomial infections (CARES) 2007–2016

20 Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem resistant Acinetobacter baumannii bloodstream infections: cefoperazone–sulbactam associated with resistance and tigecycline increased the mortality

21 In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)

22 Novel vancomycin–peptide conjugate as potent antibacterial agent against vancomycin-resistant Staphylococcus aureus

23 Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017

24 Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections

25 Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam

26 Appropriate composites of cefoperazone–sulbactam against multidrug-resistant organisms

27 Epidemiology of and risk factors for infection with extended-spectrum β-lactamase-producing carbapenem-resistant Enterobacteriaceae: results of a double case–control study

28 Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015

29 Current trends to control fungal pathogens: exploiting our knowledge in the host–pathogen interaction

30 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

31 Extensively drug-resistant Myroides odoratimimus – a case series of urinary tract infections in immunocompromised patients

32 Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

33 Overview of the development of quinolone resistance in Salmonella species in China, 2005–2016

34 Molecular analysis of multidrug resistance in clinical isolates of Shigella spp. from 2001–2010 in Kolkata, India: role of integrons, plasmids, and topoisomerase mutations

35 Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate–severe Gram-positive infections

36 High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014

37 Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

38 Host–pathogen interactions and immune evasion strategies in Francisella tularensis pathogenicity

39 Staphylococcus aureus – antimicrobial resistance and the immunocompromised child

40 Update on otitis media – prevention and treatment

41 Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

42 Recent developments in the epidemiology and management of tuberculosis – new solutions to old problems?

43 Combining antihypertensive and antihyperlipidemic agents – optimizing cardiovascular risk factor management

44 Clinical utility of fixed-combination telmisartan–amlodipine in the treatment of hypertension

45 Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension – update on clinical utility

46 Valsartan combination therapy in the management of hypertension – patient perspectives and clinical utility

47 Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)

48 Pretreatment neutrophil–lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma

49 Prevalence and predictors of left ventricular dysfunction among patients with chronic kidney disease attending Muhimbili National Hospital in Tanzania — a cross-sectional study

50 Multielectrode phased radiofrequency ablation compared with point-by-point ablation for pulmonary vein isolation – outcomes in 539 patients

51 Azilsartan alone and in combination for the treatment of hypertension – clinical utility and patient considerations

52 8-isorpostanes – markers for oxidative stress in obstructive sleep apnea patients with systolic dysfunction

53 Self-reported prevalence of heart attacks and strokes in Jamaica: a cross-sectional study. The Jamaica Health and Lifestyle Survey 2007–2008

54 Application of the susceptible–infected–recovered deterministic model in a GII.P17 emergent norovirus strain outbreak in Romania in 2015

55 The efficacy and safety of ceftaroline in the treatment of acute bacterial infection in pediatric patients – a systemic review and meta-analysis of randomized controlled trials

56 An increasing trend of neonatal invasive multidrug-resistant group B streptococcus infections in southern China, 2011–2017 [Corrigendum]

57 Association between vitamin D and latent tuberculosis infection in the United States: NHANES, 2011–2012

58 Evaluating the antimicrobial resistance patterns among major bacterial pathogens isolated from clinical specimens taken from patients in Mofid Children’s Hospital, Tehran, Iran: 2013–2018

59 A high prevalence of human T-lymphotropic virus (HTLV 1/2) infection among Afro-descendants, Esmeraldas province, Ecuador – need for the implementation of surveys and control programs

60 Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with Escherichia coli, ESBL-producing or not – a retrospective cohort study

61 Spinal brucellosis in Hulunbuir, China, 2011–2016

62 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

63 An increasing trend of neonatal invasive multidrug-resistant group B streptococcus infections in southern China, 2011–2017 [Corrigendum]

64 Association between vitamin D and latent tuberculosis infection in the United States: NHANES, 2011–2012

65 Evaluating the antimicrobial resistance patterns among major bacterial pathogens isolated from clinical specimens taken from patients in Mofid Children’s Hospital, Tehran, Iran: 2013–2018

66 A high prevalence of human T-lymphotropic virus (HTLV 1/2) infection among Afro-descendants, Esmeraldas province, Ecuador – need for the implementation of surveys and control programs

67 Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with Escherichia coli, ESBL-producing or not – a retrospective cohort study

68 Spinal brucellosis in Hulunbuir, China, 2011–2016

69 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

70 Low prevalence of resistance genes in sheltered homeless population in Marseille, France, 2014–2018

71 Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo

72 Susceptibilities of Gram-negative bacilli from hospital- and community-acquired intra-abdominal and urinary tract infections: a 2016–2017 update of the Chinese SMART study

73 Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016

74 Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate–severe Gram-positive infections [Corrigendum]

75 Silencing of OCH1 unveils the role of Sporothrix schenckii N-linked glycans during the host–fungus interaction

76 An increasing trend of neonatal invasive multidrug-resistant group B streptococcus infections in southern China, 2011–2017

77 Epidemiological and molecular analysis of avian influenza A(H7N9) virus in Shanghai, China, 2013–2017

78 Health care-associated infections – an overview

79 A multicenter epidemiology study on the risk factors and clinical outcomes of nosocomial intra-abdominal infections in China: results from the Chinese antimicrobial resistance surveillance of nosocomial infections (CARES) 2007–2016

80 Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem resistant Acinetobacter baumannii bloodstream infections: cefoperazone–sulbactam associated with resistance and tigecycline increased the mortality

81 In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)

82 Novel vancomycin–peptide conjugate as potent antibacterial agent against vancomycin-resistant Staphylococcus aureus

83 Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017

84 Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections

85 Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam

86 Appropriate composites of cefoperazone–sulbactam against multidrug-resistant organisms

87 Epidemiology of and risk factors for infection with extended-spectrum β-lactamase-producing carbapenem-resistant Enterobacteriaceae: results of a double case–control study

88 Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015

89 Current trends to control fungal pathogens: exploiting our knowledge in the host–pathogen interaction

90 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

91 Extensively drug-resistant Myroides odoratimimus – a case series of urinary tract infections in immunocompromised patients

92 Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

93 Overview of the development of quinolone resistance in Salmonella species in China, 2005–2016

94 Molecular analysis of multidrug resistance in clinical isolates of Shigella spp. from 2001–2010 in Kolkata, India: role of integrons, plasmids, and topoisomerase mutations

95 Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate–severe Gram-positive infections

96 High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014

97 Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

98 Host–pathogen interactions and immune evasion strategies in Francisella tularensis pathogenicity

99 Staphylococcus aureus – antimicrobial resistance and the immunocompromised child

100 Update on otitis media – prevention and treatment

101 Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

Keyword Connections

Journals

Research Groups

Bibliographies